CSF1R inhibition reprograms tumor-associated macrophages to potentiate anti-PD-1 therapy efficacy against colorectal cancer.

MLA

Lv, Qi, et al. “CSF1R Inhibition Reprograms Tumor-Associated Macrophages to Potentiate Anti-PD-1 Therapy Efficacy against Colorectal Cancer.” Pharmacological Research, vol. 202, Apr. 2024, p. N.PAG. EBSCOhost, https://doi.org/10.1016/j.phrs.2024.107126.

APA

Lv, Q., Zhang, Y., Gao, W., Wang, J., Hu, Y., Yang, H., Xie, Y., Lv, Y., Zhang, H., Wu, D., Hu, L., & Wang, J. (2024). CSF1R inhibition reprograms tumor-associated macrophages to potentiate anti-PD-1 therapy efficacy against colorectal cancer. Pharmacological Research, 202, N.PAG. https://doi.org/10.1016/j.phrs.2024.107126

Chicago

Lv, Qi, Yishu Zhang, Wen Gao, Juan Wang, Yaowen Hu, Hongqiong Yang, Ying Xie, et al. 2024. “CSF1R Inhibition Reprograms Tumor-Associated Macrophages to Potentiate Anti-PD-1 Therapy Efficacy against Colorectal Cancer.” Pharmacological Research 202 (April): N.PAG. doi:10.1016/j.phrs.2024.107126.